Hypertrophic Scars – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Hypertrophic Scars Market Outlook

Thelansis’s “Hypertrophic Scars Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hypertrophic Scars treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Hypertrophic Scars Overview

Hypertrophic scars are characterized as elevated, red-colored, itchy lesions that remain within the confines of the original wound area. They often start with a brownish-red hue but can fade as they age. Unlike keloids, these scars are generally less nodular and don't protrude more than 4 mm above the skin's surface. The formation of hypertrophic scars usually begins about six to eight weeks after an injury and stabilizes around six months afterward. Notably, they tend to manifest more frequently on extensor surfaces such as the elbows and knees, and if they develop over joints, they can lead to restrictive contractures. Spontaneous regression is possible without any intervention, and the severity of scarring is closely linked to the depth and site of the injury. When addressing hypertrophic scars, steroids are commonly employed as the primary treatment option for this type of scarring, though a definitive cure is not straightforward. Steroids can be administered through injections or direct topical application. Surgical removal is another approach for managing these scars. Typically, steroid injections are combined with surgical procedures and may continue for up to two years after the surgery to promote optimal healing and minimize the chances of recurrence. The prognosis for hypertrophic scarring is generally more favorable compared to keloids. These scars usually emerge soon after an injury and may increase in size for a period before gradually regressing on their own. They tend to respond better to treatments with a lower likelihood of recurring, often requiring only a single treatment approach.

• Adolescents and pregnant women are more susceptible to developing hypertrophic scars. It is estimated that approximately 70% of deep (full-thickness) burn injuries result in the formation of hypertrophic scars.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: